Biohaven Stock
Biohaven Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Vladimir Coric
- Employees
- 274
- Market cap
- $1.6 B
- IPO
- 23/09/2022
Biohaven Ltd. is a biopharmaceutical company within the healthcare sector that focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. Headquartered in New Haven, USA, the company was incorporated in 2022 and operates under the…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Biohaven stock: price history
1D
-5.7%
1W
-10.8%
1M
-10.3%
6M
-1.8%
YTD
-4.5%
1Y
-34.6%
2Y
-79.1%
5Y
–
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~51% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Biohaven
Analyst assessment of Biohaven
PRICE TARGET LOW
US$11.00
CONSENSUS
US$20.00
MEDIAN
US$19.00
PRICE TARGET HIGH
US$30.00
0
STRONG BUY
16
BUY
8
HOLD
1
SELL
0
STRONG SELL
25
TOTAL · Buy
As of: 10/09/2026
Biohaven stock metrics
P/E
-2.32
P/B
132.86
EV/EBITDA
-2.93
RETURN ON EQUITY
-1,123.5%
NET MARGIN
0.0%
DEBT/EQUITY
24.3
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.1%
FLOAT SHARES
128,559,252
AVG. DAILY VOLUME (30D)
2,681,316
Institutional holders
Comparable stocks
Frequently asked questions about Biohaven stock
What does Biohaven do?
Biohaven Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Vladimir Coric, the company employs around 274 people.
The IPO was on 23/09/2022; the stock trades on NYSE under the ticker BHVN.
What do analysts say about Biohaven stock?
25 analysts rate the stock, the consensus is Buy (as of 10/09/2026).
The average price target is US$20.00, ranging from US$11.00 to US$30.00, with a median of US$19.00.
This is an external assessment, not a statement by Market Jury.
When does Biohaven report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 51% stronger than usual.
Does Biohaven pay a dividend?
No, Biohaven currently does not pay a dividend.
Which stocks are comparable to Biohaven?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Biohaven stock analyzed?
Clicking "Analyze stock" lets five strategies assess Biohaven against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.